Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06967805Phase 2Recruiting

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead

NCT07287670Phase 2Recruiting

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Role: lead

NCT07450521Phase 1Completed

Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males

Role: lead

NCT07473323Phase 1Not Yet Recruiting

Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease

Role: lead

NCT06535841Phase 1Completed

A First-in-Human Safety Trial of MTX-474

Role: lead

NCT06401213Phase 1Completed

A First-in-Human Safety Trial of MTX-463

Role: lead

All 6 trials loaded